Is there a difference in demography and clinical characteristics in patients treated with and without bevacizumab?

Hartmann, H., Müller, J., Marschner, N., 2012.

J Clin Oncol 30, 3317–3318. doi:10.1200/JCO.2012.43.3409

Studie: Indikationsübergreifend; Indikation: Kolorektalkarzinom; Jahr: 2012; Veranstaltung: -; Journal: Journal of Clinical Oncology

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com